IP Library › Granted Patent US 12,280,066
Granted Patent B2
US 12,280,066 · App. 18/541,675 · Granted Apr 22, 2025

Methods and compositions related to glucocorticoid receptor antagonists and breast cancer

Inventors: Deng Pan (Chicago, IL); Masha Kocherginsky (Chicago, IL); Suzanne D. Conzen (Park Ridge, IL)
Assignee: The University of Chicago
A61K31/575A61J1/00A61K31/282A61K31/337A61K31/357A61K31/4745A61K31/567A61K31/58A61K31/7068A61K33/243A61K39/3955A61K45/06A61N5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,066
App. No.
18/541,675
Granted
Apr 22, 2025
Kind
B2
Abstract

Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Claims (27)

1. A method of killing breast cancer cells comprising administering to a breast cancer patient an effective amount of a combination of anti-cancer compounds, wherein the anticancer compounds comprise a glucocorticoid receptor antagonist selected from beclometasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone, mifepristone (RU-486), RU-43044, 10β-substituted steroids, 11β-aryl conjugates of mifepristone, phosphorous-containing mifepristone analogs, 11-monoaryl and 11,21 bisaryl steroids (including 11 (3-substituted steroids), octahydrophenanthrenes, spirocyclic dihydropyridines, triphenylmethanes and diaryl ethers, chromenes, dibenzyl anilines, dihyrdroquinolines, pyrimidinediones, azadecalins, aryl pyrazolo azadecalins (including 8a-benzyl isoquinolones, N-substituted derivatives, bridgehead alcohol and ethers, bridgehead amines, ORG-34517 (Merck), dexamethasone mesylate (Dex-Mes), dexamethasone oxetanone (Dex-Ox), deoxycorticosterone (DOC), CORT 0113083 and CORT 00112716,

and a chemotherapeutic agent.

2. A method of treating breast cancer in a patient comprising administering to the patient an effective amount of glucocorticoid receptor antagonist selected from beclometasone, betamethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, triamcinolone, mifepristone (RU-486), RU-43044, 10β-substituted steroids, 11β-aryl conjugates of mifepristone, phosphorous-containing mifepristone analogs, 11-monoaryl and 11,21 bisaryl steroids (including 11 (3-substituted steroids), octahydrophenanthrenes, spirocyclic dihydropyridines, triphenylmethanes and diaryl ethers, chromenes, dibenzyl anilines, dihyrdroquinolines, pyrimidinediones, azadecalins, aryl pyrazolo azadecalins (including 8a-benzyl isoquinolones, N-substituted derivatives, bridgehead alcohol and ethers, bridgehead amines, ORG-34517 (Merck), dexamethasone mesylate (Dex-Mes), dexamethasone oxetanone (Dex-Ox), deoxycorticosterone (DOC), CORT 0113083 and CORT 00112716,

and a chemotherapeutic agent.

3. The method of treating breast cancer in a patient of claim 2 , wherein said breast cancer comprises chemotherapy-insensitive breast cancer cells, the method comprising administering to a breast cancer patient an effective amount of said glucocorticoid receptor antagonist followed by chemotherapy agent.

4. The method of treating breast cancer in a patient of claim 2 , comprising administering to said breast cancer patient an effective amount of said glucocorticoid receptor antagonist followed by at least one apoptosis-inducing agent.

5. The method for treating breast cancer in a patient of claim 2 , further comprising:

a) administering radiation or at least a first chemotherapeutic to the patient;

b) subsequently administering an effective amount of said glucocorticoid receptor antagonist to the patient;

c) administering radiation again or at least a second chemotherapeutic to the patient after the glucocorticoid receptor antagonist is administered to the patient.

6. The method for treating breast cancer in a patient of claim 2 , further comprising:

a) administering an effective amount of said glucocorticoid receptor antagonist to the patient, wherein the patient expresses a detectable level of glucocorticoid receptor prior to administration of the GR antagonist;

b) then administering an effective amount of radiation or at least one chemotherapeutic.

7. A method for evaluating a patient with breast cancer comprising:

a) measuring the activity level of glucocorticoid receptor (GR) from a biological sample from the patient containing breast cancer cells;

b) measuring the expression level of estrogen receptor (ER) in breast cancer cells from the patient;

c) identifying the patient as having or not having a risk factor for cancer recurrence based on measurements in a) and b).

8. The method for evaluating a patient with breast cancer of claim 7 , further comprising

calculating a prognosis score for the patient based on the measurements in a) and b).

9. The method for evaluating a patient with breast cancer of claim 7 , further comprising:

identifying the patient as having a poor prognosis if the patient is determined to have i) an activity level of glucocorticoid receptor that is higher than the activity level of glucocorticoid receptor in normalized control sample and ii) a expression level of estrogen receptor expression that is lower than the expression level of estrogen receptor in a normalized control sample.

10. The method for evaluating a patient with breast cancer of claim 7 , further comprising:

categorizing the patient as i) GR+ or GR− based on the level of glucocorticoid activity assayed in the biological sample and compared to a predetermined threshold value for GR activity; and ii) ER+ or ER− based on the level of estrogen receptor expression assayed in the biological sample and compared to a predetermined threshold value for ER expression.

11. The method for evaluating a patient with breast cancer of claim 7 , further comprising:

prognosing the patient based on the measurements in a) after obtaining information about the level of estrogen receptor expression in breast cancer cells of the patient.

12. The method for evaluating a patient with breast cancer of claim 7 , further comprising

identifying the patient as having a poor prognosis if the patient is determined to have a glucocorticoid receptor activity level in the 65th percentile or above based on breast cancer patients whose levels of estrogen receptor are in the 35th percentile or below.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2023
From: PAN, DENG; KOCHERGINSKY, MASHA; CONZEN, SUZANNE D.
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 065889/0498 →
Continuity (8)
Continuation 17577882 · Jan 18, 2022
Continuation 16596342 · Oct 8, 2019
Continuation 15448827 · Mar 3, 2017
Continuation 14296127 · Jun 4, 2014
Continuation 14172051 · Feb 4, 2014
Continuation 13071363 · Mar 24, 2011
Provisional Application 61317182 · Mar 24, 2010
Related Publication 20240148754A1 · May 9, 2024
References Cited (74)
US 8003689B2 · Veverka · 2011 [cited by applicant]
US 8658128B2 · Altschul et al. · 2014 [cited by applicant]
US 8710035B2 · Pan et al. · 2014 [cited by applicant]
US 9114147B2 · Altschul et al. · 2015 [cited by applicant]
US 9149485B2 · Pan et al. · 2015 [cited by applicant]
US 9623032B2 · Pan et al. · 2017 [cited by applicant]
US 10071130B2 · Conzen · 2018 [cited by applicant]
US 10441596B2 · Pan et al. · 2019 [cited by applicant]
US 11234990B2 · Pan et al. · 2022 [cited by applicant]
US 20020115613A1 · Kumar · 2002 [cited by applicant]
US 20050124533A1 · Schatzberg et al. · 2005 [cited by applicant]
US 20060063748A1 · Belanoff · 2006 [cited by applicant]
US 20080287419A1 · Bruncko et al. · 2008 [cited by applicant]
US 20100135956A1 · Gant et al. · 2010 [cited by applicant]
US 20140186367A1 · Pan · 2014 [cited by applicant]
US 20140315866A1 · Pan et al. · 2014 [cited by applicant]
US 20170182066A1 · Pan et al. · 2017 [cited by applicant]
WO 2009064738A2 · 2009 [cited by applicant]
“Data Sheet: Glucocorticoid Receptor mouse monoclonal antibody NCL-GCR”, Novocastra Laboratories Ltd., Available Online at: http://www.ebiotrade.com/buyf/Novocastra/data/hrerp/gcr.pdf, Accessed from internet at Jun. 7, … [cited by applicant]
U.S. Appl. No. 14/172,051 , Non-Final Office Action, Mailed On Mar. 10, 2015, 9 pages. [cited by applicant]
U.S. Appl. No. 14/172,051 , Notice of Allowance, Mailed On Jun. 24, 2015, 11 pages. [cited by applicant]
U.S. Appl. No. 14/172,051 , Notice of Allowance, Mailed On Apr. 30, 2015, 5 pages. [cited by applicant]
U.S. Appl. No. 14/296,127 , Final Office Action, Mailed On Jul. 5, 2016, 9 pages. [cited by applicant]
U.S. Appl. No. 14/296,127 , Non-Final Office Action, Mailed On Dec. 17, 2015, 10 pages. [cited by applicant]
U.S. Appl. No. 14/296,127 , Non-Final Office Action, Mailed On Sep. 14, 2016, 7 pages. [cited by applicant]
U.S. Appl. No. 14/296,127 , Notice of Allowance, Mailed On Dec. 8, 2016, 9 pages. [cited by applicant]
U.S. Appl. No. 14/296,127 , “Restriction Requirement”, Oct. 8, 2015, 11 pages. [cited by applicant]
U.S. Appl. No. 14/451,207, Notice of Withdrawal from Issue under 37 CFR 1.313 (b), Feb. 4, 2016, 2 pages. [cited by applicant]
U.S. Appl. No. 17/577,882 , Non-Final Office Action, Mailed On Jul. 14, 2023, 12 pages. [cited by applicant]
U.S. Appl. No. 17/577,882 , Notice of Allowance, Mailed On Oct. 23, 2023, 5 pages. [cited by applicant]
U.S. Appl. No. 61/317,182 , “U.S. Provisional Application No.”, Mar. 24, 2010, 72 pages. [cited by applicant]
Belanoff et al., “Selective Glucocorticoid Receptor {Type II) Antagonists Prevent Weight Gain Caused by Olanzapine in Rats”, European Journal of Pharmacology, vol. 655, No. 1-3, Mar. 25, 2011, pp. 117-120. [cited by applicant]
Belova et al., “Glucocorticoid Receptor Expression in Breast Cancer Associates with Older Patient Age”, Breast Cancer Research and Treatment, vol. 116, No. 3, Aug. 2009, pp. 441-447. [cited by applicant]
Cho et al., “Role of Activation function Domain-1, DNA Binding, and Coactivator GRIP1 in the Expression of Partial Agonist Activity of Glucocorticoid Receptor-Antagonist Complexes”, Biochemistry, vol. 44, No. 9, Mar. 8,… [cited by applicant]
Clark , “Glucocorticoid Receptor Antagonists”, Current Topics in Medicinal Chemistry, vol. 8, No. 9, Jun. 1, 2008, pp. 813-838. [cited by applicant]
Colleoni et al., “Response to Primary Chemotherapy in Breast Cancer Patients with Tumors Not Expressing Estrogen and Progesterone Receptors”, Annals of Oncology, vol. 11, No. 8, Aug. 1, 2000, pp. 1057-1059. [cited by applicant]
Dennis , “Off by a Whisker”, Nature, vol. 442, Aug. 7, 2006, pp. 739-741. [cited by applicant]
Desmedt et al., “Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series”, Clinical Cancer Research, vol. 13, No. 11,… [cited by applicant]
Gaddy et al., “Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells”, Clinical Cancer Research, vol. 10, No. 15, Aug. 1, 2004,… [cited by applicant]
Grover et al., “The Initiation of Breast and Prostate Cancer”, Carcinogenesis, vol. 23, No. 7, Jul. 1, 2002, pp. 1095-1102. [cited by applicant]
Gura , “Systems for Identifying New Drugs are Often Faulty”, Science, Cancer Models, vol. 278, No. 5340, Nov. 7, 1997, pp. 1041-1042. [cited by applicant]
Hein et al., “Click Chemistry, A powerful Tool for Pharmaceutical Sciences”, Pharmaceutical Research, vol. 25, No. 10, Oct. 2008, pp. 2216-2230. [cited by applicant]
Henderson et al., “Estrogens as a Cause of Human Cancer: the Richard and Hinda Rosenthal Foundation Award Lecture”, Cancer Research, vol. 48, No. 2, Jan. 15, 1988, pp. 246-253. [cited by applicant]
Huang et al., “Reversal Effect of Mifepristone on Adriamycin Resistance in Human Breast Cancer Cell Line MCF-7/ADM in Vitro and in Vivo”, Journal of Central South University, Medical Sciences, vol. 35,No. 6, Jun. 2010, … [cited by applicant]
Keen et al., “The Biology of Breast Carcinoma”, Cancer, vol. 97, No. 3, Feb. 1, 2003, pp. 825-833. [cited by applicant]
Kriaucionis et al., “The Nuclear DNA Base 5-Hydroxymethylcytosine is Present in Brain and Enriched in Purkinje Neurons”, Science, vol. 324, No. 5929, May 15, 2009, 5 pages. [cited by applicant]
Loi et al., “Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade”, Journal of Clinical Oncology, vol. 25, No. 10, Apr. 1, 2007, pp. 1239-1246. [cited by applicant]
Loi et al., “Predicting Prognosis Using Molecular Profiling in Estrogen Receptor-Positive Breast Cancer Treated With Tamoxifen”, BMC Genomics, vol. 9, No. 239, May 22, 2008, pp. 1-12. [cited by applicant]
Lucci et al., “Modification of Ceramide Metabolism Increases Cancer Cell Sensitivity to Cytotoxics”, International Journal of Oncology, vol. 15, No. 3, Sep. 1999, pp. 541-546. [cited by applicant]
Ma et al., “IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-Gamma”, Journal of Immunology, vol. 171, No. 2, Jul. 15, 2003, pp. 60… [cited by applicant]
Melhem et al., “Administration of Glucocorticoids to Ovarian Cancer Patients is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues”, Clinical Cancer Research, vol. 15, No. 9, M… [cited by applicant]
Mikosz et al., “Glucocorticoid Receptor-Mediated Protection from Apoptosis is Associated with Induction of the Serine/Threonine Survival Kinase Gene, sgk-1”, The Journal of Biological Chemistry, vol. 276, No. 20, May 18… [cited by applicant]
Minn et al., “Genes that Mediate Breast Cancer Metastasis to Lung”, Nature, vol. 436, No. 7050, Jul. 28, 2005, pp. 518-524. [cited by applicant]
Moran et al., “The Glucocorticoid Receptor Mediates a Survival Signal in Human Mammary Epithelial Cells”, Cancer Research, vol. 60, No. 4, Feb. 15, 2000, pp. 867-872. [cited by applicant]
Moses et al., “The Growing Applications of Click Chemistry”, Chemical Society Reviews, vol. 36, No. 8, May 2007, pp. 1249-1262. [cited by applicant]
Neckers et al., “Heat-Shock Protein 90 Inhibitors As Novel Cancer Chemotherapeutic Agents”, Breast Disease, Available Online at: https://content.iospress.com/articles/breast-disease/bd000102 vol. 15, No. 1, Jun. 1, 2002… [cited by applicant]
Pan et al., “Activation of the Glucocorticoid Receptor is Associated with Poor Prognosis in Estrogen Receptor-Negative Breast Cancer”, Cancer Research, vol. 71, No. 20, Oct. 15, 2011, pp. 6360-6370. [cited by applicant]
Pan et al., “Identification of Glucocorticoid Receptor (GR) Signatures in Primary Human Breast Cancer: Association with Relapse-Free Survival Time”, Poster Presented by S.D. Conzen as a Short Talk, presented at Nuclear … [cited by applicant]
Pang et al., “Dexamethasone Decreases Xenograft Response to Paclitaxel Through Inhibition of Tumor Cell Apoptosis”, Cancer Biology & Therapy, vol. 5, No. 8, Aug. 2006, pp. 933-940. [cited by applicant]
Peeters et al., “Differential Effects of the New Glucocorticoid Receptor Antagonist ORG 34517 and RU486 (Mifepristone) on Glucocorticoid Receptor Nuclear Translocation in the AtT20 Cell Line”, Annals of the New York Aca… [cited by applicant]
Pike et al., “Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk”, Epidemiologic Reviews, vol. 15, No. 1, Jan. 1, 1993, pp. 17-30. [cited by applicant]
Reagan-Shaw et al., “Dose Translation from Animal to Human Studies Revisited”, The Faseb Journal, vol. 22, Mar. 2007, pp. 659-661. [cited by applicant]
Robinson et al., “Octahydrophenanthrene-2,7-diol Analogues as Dissociated Glucocorticoid Receptor Agonists: Discovery and Lead Exploration”, Journal of Medicinal Chemistry, vol. 52, No. 6, Mar. 26, 2009, pp. 1731-1743. [cited by applicant]
Sims et al., “The Removal of Multiplicative, Systematic Bias Allows Integration of Breast Cancer Gene Expression Datasets—Improving Meta-Analysis and Prediction of Prognosis”, BMC Medical Genomics, vol. 1, No. 42, Sep. … [cited by applicant]
Smith et al., “Expression of Glucocorticoid and Progesterone Nuclear Receptor Genes in Archival Breast Cancer Tissue”, Breast Cancer Research, vol. 5, No. 1, 2003, pp. R9-R12. [cited by applicant]
Smith et al., “Progesterone, Glucocorticoid, but Not Estrogen Receptor mRNA is Altered in Breast Cancer Stroma”, Cancer Letters, vol. 255, No. 1, Sep. 18, 2007, pp. 77-84. [cited by applicant]
Sorlie et al., “Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications”, Proceedings of the National Academy of Sciences of the United States of America, vol. 98, No. 19, S… [cited by applicant]
Sotiriou et al., “Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade to Improve Prognosis”, Journal of the National Cancer Institute, vol. 98, No. 4, Feb. 15, 2006, pp. 262… [cited by applicant]
Srinivas et al., “Proteomics for Cancer Biomarker Discovery”, Clinical Chemistry, vol. 48, No. 8, Aug. 2002, pp. 1160-1169. [cited by applicant]
Sui et al., “Estrogen Receptor a Mediates Breast Cancer Cell Resistance to Paclitaxel Through Inhibition of Apoptotic Cell Death”, Cancer Research, vol. 67, No. 11, Jun. 1, 2007, pp. 5337-5344. [cited by applicant]
Wang et al., “Gene-Expression Profiles to Predict Distant Metastasis of Lymph-Node-Negative Primary Breast Cancer”, The Lancet, vol. 365, No. 9460, Feb. 19, 2005, pp. 671-679. [cited by applicant]
Wu et al., “Glucocorticoid Receptor Activation Signals Through Forkhead Transcription Factor 3a in Breast Cancer Cells”, Molecular Endocrinology, vol. 20, No. 10, Oct. 1, 2006, pp. 2304-2314. [cited by applicant]
Wu et al., “Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes that are Associated with Inhibition of Apoptosis in Breast Epithelial Cells”, Cancer Research, vol. 64, No. 5, Mar. 1, 2004, pp. 1757-1764. [cited by applicant]
Wu et al., “Prevalent Expression of the Immunostimulatory MHC Class I Chain-Related Molecule Is Counteracted by Shedding in Prostate Cancer”, Journal of Clinical Investigation, vol. 114, No. 4, Aug. 16, 2004, pp. 560-56… [cited by applicant]